{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:39:09Z","timestamp":1792463949055,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,19]]},"DOI":"10.7759\/cureus.118195","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:52:35Z","timestamp":1792461155000},"source":"Crossref","is-referenced-by-count":0,"title":["Diabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Review"],"prefix":"10.7759","author":[{"given":"Jamal","family":"Muhsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. diabetes. (2026). Accessed: October 11, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"ref2","unstructured":"World Health Organization. obesity and overweight. (2026). Accessed: October 11, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo ZL","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, et al.. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021, 128:1580-91. 10.1016\/j.ophtha.2021.04.027","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70999-7","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy","volume":"123","author":"Hattenhauer MG","year":"1997","unstructured":"Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997, 123:103-7. 10.1016\/S0002-9394(14)70999-7","journal-title":"Am J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll T","year":"2018","unstructured":"Vilsb\u00f8ll T, Bain SC, Leiter LA, et al.. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018, 20:889-97. 10.1111\/dom.13172","journal-title":"Diabetes Obes Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1815","article-title":"HbA(1c) change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression","volume":"44","author":"Bethel MA","year":"2021","unstructured":"Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA(1c) change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care. 2021, 44:290-6. 10.2337\/dc20-1815","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-025-06466-8","article-title":"Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study","volume":"68","author":"Buckley AJ","year":"2025","unstructured":"Buckley AJ, Tan GD, Gruszka-Goh M, et al.. Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study. Diabetologia. 2025, 68:2069-76.","journal-title":"Diabetologia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes","volume":"8","author":"Ramsey DJ","year":"2025","unstructured":"Ramsey DJ, Makwana B, Dani SS, et al.. GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes. JAMA Netw Open. 2025, 8:e2526321. 10.1001\/jamanetworkopen.2025.26321","journal-title":"JAMA Netw Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-026-07430-x","article-title":"Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes","author":"Francisco C","year":"2026","unstructured":"Francisco C, Neves JS, Laiginhas R, Falc\u00e3o M. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes. Graefes Arch Clin Exp Ophthalmol. 2026, 10.1007\/s00417-026-07430-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway JT","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, et al.. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024, 142:732-9. 10.1001\/jamaophthalmol.2024.2296","journal-title":"JAMA Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai CX","year":"2025","unstructured":"Cai CX, Hribar M, Baxter S, et al.. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025, 143:304-14. 10.1001\/jamaophthalmol.2024.6555","journal-title":"JAMA Ophthalmol"},{"key":"ref13","unstructured":"PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. (2025). Accessed.  September 23, 2026: https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozem...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1005064","article-title":"Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies","volume":"23","author":"Chrzanowski J","year":"2026","unstructured":"Chrzanowski J, Walicka M, Burzy\u0144ski J, Zara\u015b M, Michalak A, Fendler W. Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. PLoS Med. 2026, 23:e1005064. 10.1371\/journal.pmed.1005064","journal-title":"PLoS Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm E","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007, 4:e296. 10.1371\/journal.pmed.0040296","journal-title":"PLoS Med"},{"key":"ref16","unstructured":"Billing and coding. visual field examination (A57637). (2025). Accessed: October 11, 2026: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/article.aspx?articleId=57637."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14445","article-title":"Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: a meta-analysis of clinical studies emphasising retinal changes as a primary outcome","volume":"53","author":"Kapoor I","year":"2025","unstructured":"Kapoor I, Sarvepalli SM, D'Alessio DA, Hadziahmetovic M. Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: a meta-analysis of clinical studies emphasising retinal changes as a primary outcome. Clin Exp Ophthalmol. 2025, 53:67-75. 10.1111\/ceo.14445","journal-title":"Clin Exp Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2025-005424","article-title":"Semaglutide and diabetic retinopathy: an OHDSI network study","volume":"13","author":"Cai CX","year":"2025","unstructured":"Cai CX, Nishimura A, Baxter S, et al.. Semaglutide and diabetic retinopathy: an OHDSI network study. BMJ Open Diabetes Res Care. 2025, 13:e005424. 10.1136\/bmjdrc-2025-005424","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2026.01.013","article-title":"Tirzepatide and reduced risk of diabetic retinopathy and related complications: a multicenter US cohort study","volume":"133","author":"Shah J","year":"2026","unstructured":"Shah J, Razavi P, Festok M, Ahmed H, Mahrous MA, Kovacs KD, Kiss S. Tirzepatide and reduced risk of diabetic retinopathy and related complications: a multicenter US cohort study. Ophthalmology. 2026, 133:728-32. 10.1016\/j.ophtha.2026.01.013","journal-title":"Ophthalmology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/540803-diabetic-retinal-disease-onset-and-progression-during-established-semaglutide-or-tirzepatide-treatment-a-retrospective-comparative-cohort-study-with-a-descriptive-regional-nonarteritic-anterior-ischemic-optic-neuropathy-naion-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:52:37Z","timestamp":1792461157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/540803-diabetic-retinal-disease-onset-and-progression-during-established-semaglutide-or-tirzepatide-treatment-a-retrospective-comparative-cohort-study-with-a-descriptive-regional-nonarteritic-anterior-ischemic-optic-neuropathy-naion-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.118195","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,19]]}}}